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Abstract
Background: An HIV vaccine could substantially impact the epidemic. However, risk compensation (RC), or post-vaccination
increase in risk behavior, could present a major challenge. The methodology used in previous studies of risk compensation
has been almost exclusively individual-level in focus, and has not explored how increased risk behavior could affect the
connectivity of risk networks. This study examined the impact of anticipated HIV vaccine-related RC on the structure of
high-risk drug users’ sexual and injection risk network.
Methods: A sample of 433 rural drug users in the US provided data on their risk relationships (i.e., those involving recent
unprotected sex and/or injection equipment sharing). Dyad-specific data were collected on likelihood of increasing/
initiating risk behavior if they, their partner, or they and their partner received an HIV vaccine. Using these data and social
network analysis, a "post-vaccination network" was constructed and compared to the current network on measures relevant
to HIV transmission, including network size, cohesiveness (e.g., diameter, component structure, density), and centrality.
Results: Participants reported 488 risk relationships. Few reported an intention to decrease condom use or increase
equipment sharing (4% and 1%, respectively). RC intent was reported in 30 existing risk relationships and vaccination was
anticipated to elicit the formation of five new relationships. RC resulted in a 5% increase in risk network size (n = 142 to
n = 149) and a significant increase in network density. The initiation of risk relationships resulted in the connection of
otherwise disconnected network components, with the largest doubling in size from five to ten.
Conclusions: This study demonstrates a new methodological approach to studying RC and reveals that behavior change
following HIV vaccination could potentially impact risk network connectivity. These data will be valuable in parameterizing
future network models that can determine if network-level change precipitated by RC would appreciably impact the
vaccine’s population-level effectiveness.
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Introduction
Preventive HIV vaccines have the potential to curtail the HIV
epidemic. However, many have voiced concerns that HIV
vaccination could elicit increased HIV risk behavior among
vaccine recipients. This phenomenon, or ‘risk compensation’,
occurs when diminished perceived susceptibility resulting from
participation in some preventive intervention causes a subsequent
increase in risk behavior [1]. Given that the first HIV vaccines on
the market are likely to be only partially effective, risk
compensation could substantially dampen and, in some circum-
stances, offset the vaccine’s public health benefit [2–5]. In fact,
some models have predicted that with a combination of frequent
risk compensation and low vaccine efficacy, an HIV vaccine
campaign could actually increase HIV incidence [2,3].
Findings on the hypothetical likelihood that HIV vaccinated
individuals will engage in risk compensation have been mixed. In
HIV vaccine acceptability studies implemented in diverse settings,
participants have expressed concern that others would increase
their sexual risk behavior if vaccinated [6–10]. However, in studies
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asking participants about their personal likelihood of risk
compensation, fewer anticipate behavioral changes [11–13].
Findings from research embedded within HIV vaccine trials have
generally identified no substantial increase in risk behavior during
trial participation [14–21], though there is some evidence to the
contrary [22].
The methodology employed in most HIV vaccine risk
compensation studies to date has focused exclusively on individ-
uals. Despite an abundance of evidence suggesting that social
networks can play an important role in HIV and sexually
transmitted infection (STI) transmission [23–31], HIV risk
behavior [25,32,33], and involvement in preventive interventions
[34–36], the HIV vaccine acceptability literature is devoid of
insights into the network-level dynamics of risk compensation.
Previous individual-level studies have captured if and to what
degree individuals will engage in risk compensation [e.g., [6,37–39],
but they have not captured with whom. Consequently, there is
currently a gap in understanding about the ability of HIV
vaccination to alter the dynamics and structure of HIV risk
networks. Individual-level measures have been used to inform risk
compensation parameters in mathematical models aimed at
determining the efficacy required for an HIV vaccine to achieve
impact on population-wide HIV incidence (e.g., male-initiated
condom use [3,40], condom use [2,41], number of partners [5,41],
number of injections and needle sharing [42]). However, if risk
compensation increases the connectivity of risk networks, the
impact of risk compensation on HIV incidence may be
underestimated. HIV vaccination inherently will disrupt the
transmission of HIV through risk networks, but the degree of
disruption will depend on behavioral changes and the network
position of those who engage in risk compensation. Even minor
changes in network configuration may affect epidemic potential,
but improved understanding of anticipated network-level changes
is needed to inform network models that can estimate the
effectiveness of community HIV vaccine initiatives.
The current study used network analysis to examine drug users’
risk relationships and anticipated risk compensation. The current
risk network of participants was compared to a simulated "post-
vaccination" risk network, constructed according to participants’
anticipated behavior change (under variable hypothetical vacci-
nation scenarios) with each of their current partners and new
partners. The overarching aim of the study was to introduce a new
methodological and conceptual approach for examining risk
compensation in the context of HIV vaccination.
Methods
Sample
This study was implemented in the context of the ongoing
longitudinal Social Networks among Appalachian People (SNAP)
study, the methods of which have been described in detail
elsewhere [43,44]. The purpose of SNAP is to examine the
epidemiology of HIV, hepatitis C, and herpes-simplex 2 among
illicit drug users in a rural Appalachia in the United States.
Eligibility criteria for the study included being at least 18 years of
age, residing in an Appalachian county in Kentucky, and non-
medical use of prescription opioids, heroin, crack/cocaine or
methamphetamine to get high in the prior 30 day period.
Participants (n = 503) were recruited from November 2008 to
August 2010, using respondent driven sampling. Participants
completed interviewer-administered questionnaires and HIV
testing at baseline and every six months afterward. From March
2012 to May 2013, 435 participants completed their 24-month
follow-up assessment. All participants tested HIV negative using
the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test
(OraSure, Bethlehem, PA).
Following their 24-month interview, 433 participants were
invited to complete an interviewer-administered questionnaire on
their attitudes toward HIV vaccination and intent to change
behavior if vaccinated against HIV. Two 24-month SNAP
participants were not invited, as they were interviewed in jail
and time-constraints prohibited the interviewers’ ability to
administer the questionnaire. All invited participants provided
written informed consent to participate and were compensated $35
for their time. The protocol was approved by the University of
Kentucky’s Institutional Review Board and a Certificate of
Confidentiality was obtained.
Network data collection
The SNAP interview included a name-generator questionnaire
that was used to establish drug, sex, and social support networks.
The focus of the present study is the ’risk network’, which consists
of sexual relationships and/or relationships in which partners
engaged in injection drug use together in the past 6 months.
Participants gave the first name and last initial, age, and gender of
each of their risk partners (a maximum of twenty-four partners
could be named). The reported names and demographic
information were then cross-referenced against those of others
enrolled in the study to construct the network of relationships
among participants (i.e. the ’sociometric network’). If the
relationship could not be confirmed through the cross-referencing
procedure, the community-based interviewers were consulted for
their knowledge of reported relationships. If cross-referencing nor
consultation of interviewers revealed a confirmed linkage, the
named network member was determined to not be enrolled in the
study (i.e. outside of the sociometric network).
Two versions of the risk network were constructed: an Expansive
Network, which included all named alters (study participants and
non-participants), and a Sociometric Network, which only included
relationships between SNAP participants. For analysis, each
network was represented in the form of an actor-by-actor
adjacency matrix, Aij (example shown in Figure 1). Network
analysis and visualization were conducted using UCINET (version
6) [45] and NetDraw (version 2) [46].
Risk Behavior. For the present analyses, four behavioral
networks were constructed. One network contained valued data
representing the current frequency of HIV risk behavior; the
values represented the sum of three Likert scales on which
participants rated the frequency of any unprotected sex (0 = always
use condoms, 1 = use condoms half the time, 2 = use condoms less
than half the time, 3 = never use condoms) and frequency of
needle and cooker sharing (each measured on 4-point scales:
0 = none, 1 = less than once per month, 2 = monthly, 3 = weekly,
4 = daily) with the alter in the past 6 months. Thus, the value for
the summed risk behavior scale could range from 0 to 11. This
network was considered to be the "pre-vaccination network",
as it represented risk behavior in the absence of an HIV vaccine.
Of note, the pre-vaccination network was ‘symmetrized’ for
analysis. Symmetrized networks do not take into account who
reported the information; for example, if one person reported
sharing works with an alter, the relationship was presumed to be
reciprocal. All data (binary, ordinal and continuous) were
symmetrized by taking the maximum value reported for each
relationship.
Risk Compensation. For each sex partner and/or partner
with whom drug injection equipment was shared, respondents
were asked about their likelihood of increasing risk behavior if
they, their partner, or both they and their partner received an HIV
Risk Compensation’s Network-Level Impact
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vaccine. Specifically, respondents were asked three items to assess
sex-related risk compensation, "If [you/alter/you and alter] got an
HIV vaccine that was 90% effective, would you use a condom with
them… [‘Much less often’ (+2), ‘Less often’ (+1), ‘More often’ (21),
‘Much more often’ (22), ‘We wouldn’t change how often we used
a condom’ (0)]". Respondents were also asked three injection-
related items, "If [you/alter/you and alter] got an HIV vaccine
that was 90% effective, would you share injection equipment…"
[‘Much less often’ (22), ‘Less often’ (21), ‘More often’ (+1), ‘Much
more often’ (+2), ‘We wouldn’t change how often we shared
equipment’ (0)]. Participants were also asked about alters’ HIV
status.
Respondents were also given the option to name new
individuals with whom they would initiate risk behavior if they
received the HIV vaccine. Specifically, respondents were asked,
‘‘Imagine that you got an HIV vaccine that was 90% effective. Is
there anyone else you can think of who you may start [having sex/
sharing works] with? For example, [list of all social support, drug,
and sex network members named in the SNAP interview].’’
Respondents then gave the name (first and last initial), age, and
gender of each individual. These data were cross-referenced using
the same procedures described above to determine if the new
relationship was with someone participating in the SNAP study.
Each new relationship was conservatively assigned a value of "1"
in the post-vaccination network (described below).
The symmetrized post-vaccination network was construct-
ed using the risk compensation data. The maximum values from
the three sexual and injection-related risk compensation questions
were added to the Likert scale ratings given for the dyad’s current
unprotected sex and equipment sharing behavior, respectively.
The resulting condom use and equipment sharing ratings were
then summed to produce a valued "post-vaccination network"
representing each dyad’s frequency of risk behavior in the
presence of HIV vaccination. An example of this process is shown
in Figure 1. Note that the post vaccination matrix was
symmetrized by taking the maximum value reported for each
relationship, as demonstrated by the numbers in parentheses in
Figure 1.
Statistical Analyses
To examine changes that may occur to the overall risk network
structure in the presence of HIV vaccination, symmetrized
versions of the pre-vaccination and post-vaccination risk networks
were compared. For each network, structural measures of network
size, cohesiveness (diameter, component structure, density, and k-
cores) and centrality were computed. Each of these measures were
chosen a priori based on evidence that they can play a role in
network-level HIV and STI transmission and related behaviors in
risk networks [23,24,26,27,32,47–50]. Network size, or diameter, is
the length of the longest path in the network [51]. Components are
network structures within which all individuals are connected
directly or indirectly through at least one path [52]. Isolates are
participants who are disconnected from everyone in the network.
Density, for binary matrices, is the number of connections in the
network reported as a fraction of the total connections possible.
For valued data, density represents the average value of
relationships within the network [52]. The density of the two
networks was compared by using a bootstrap paired sample t-test
conducted in UCINET. The paired sample t-test of density on the
valued networks determined if there was a difference in the mean
overall tie strengths of the pre- and post-vaccination networks [52].
Network Centralization [53], based on computation of degree
centrality [53], represents the degree to which the networks are
centralized around one or a few actors [54]. The centralization
value, which ranges from 0 to 1, reflects the extent to which all
network members are connected through one central actor (i.e.
visualized in the shape of a star) [51,53]. Higher values of
centralization are indicative of more hierarchy [54]. Finally, k-cores
capture information on participants’ location within cohesive risk
network subgroups. A k-core is a maximal subgroup of individuals
within a network that are all connected to at least k other members
in the group. For example, a 2-core refers to a group of two or
more people who are connected to at least two other members of
the group [49]. Two-cores are hypothesized to be conducive to
HIV and STI transmission [26,49]; thus, for the present analysis,
networks were compared in terms of the number of 2-cores present
in the network.
Figure 1. Illustration of procedure for constructing pre- and post-vaccination risk networks for comparison. Figure 1 displays a
network of risk relationships among participants A, B, C and D. The corresponding adjacency matrixes are also presented. The values of the pre- and
post-vaccination network ties represent frequency of HIV risk behavior, or the sum of three Likert scales on which participants rated the frequency of
unprotected sex and frequency of needle and cooker sharing with the alter. Values in the risk compensation matrix represent the degree of behavior
change anticipated to occur after HIV vaccination, with negative numbers representing a decrease in risk behavior, zeros representing no change,
and positive numbers representing risk compensation. To construct the post-vaccination matrix, the risk compensation matrix was added to the pre-
vaccination matrix. Also, Participant D reported that they would initiate a risk relationship with Participant B, so a tie was added and a one was
entered in the corresponding cell of the post-vaccination matrix. Numbers in parentheses represent the symmetrized version of the network; the
symmetrized version was used for analysis.
doi:10.1371/journal.pone.0101047.g001
Risk Compensation’s Network-Level Impact
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Of note, most indices required dichotomization of valued data;
however, degree centrality, centralization, and density could also
be computed on valued data. For these three indices, the valued
and binary comparisons are presented.
Results
Participants were predominantly White (94%), 45% were
female, and only 25% were married. The median age of
participants was 34 years (range: 21–68). Slightly over half (58%)
had graduated from high school, 39% were unemployed, and the
median monthly income (from all sources) was $698. Most (82%)
reported at least one sexual partner in the past 6 months, 24%
reported having multiple partners, 71% reported unprotected sex
with at least one partner in the past 6 months, and 20% reported
unprotected sex with a person who injects drugs in the past 6
months.
The risk network is shown in Figure 2. Of the 433 participants,
353 reported at least one sexual relationship and 45 reported a
relationship that involved sharing drug injection equipment. All
alters were reported to be HIV negative. Overall, the symmetrized
network contained 458 sexual relationships (two involving sex
between two men), 368 of which involved unprotected sex. The
network included 65 relationships that involved equipment
sharing, including 34 that involved equipment sharing and
unprotected sex. Figure 3 displays the overlap between the
injection and sexual relationships and displays the number of
sociometric ties (in parentheses) relative to the number of
expansive network ties.
Risk compensation in current relationships
Figure 4 shows relationships involving intended risk compen-
sation (shown as red lines). There were 30 relationships in which
the respondent reported a likelihood of risk compensation,
including three that would involve increased equipment sharing
and 27 that would involve increased unprotected sex (there were
no relationships involving intent to increase equipment sharing and
unprotected sex). There were some individuals who would increase
their sexual risk behavior with many partners, including one
person that reported risk compensation for six sexual relationships
and another who reported it for four relationships. Overall, sexual
risk compensation resulted in the addition of fourteen relationships
to the risk network (i.e. individuals who previously always used
condoms would begin having unprotected sex); the other sixteen
relationships involving intended risk compensation occurred
within relationships already involving either unprotected sex or
equipment sharing. Of note, reported intention to increase condom
use after HIV vaccination resulted in the removal of four
relationships in the risk network.
As shown in Table 1, which describes responses to the risk
compensation questions, the likelihood of risk compensation did
not vary substantially by vaccination scenario (i.e. vaccination of
self, partner, or of self and partner). Sexual risk compensation was
intended in only 5.3% of sexual relationships in the network and
risk compensation related to equipment sharing was only intended
in 4.4% of equipment sharing relationships. Interestingly, condom
use was intended to increase after HIV vaccination in 4.7% of
sexual relationships. Overall, the vast majority of participants
reported they would not change their sexual or injection-related
risk behavior under any vaccination scenario (91.2% and 93.3%,
respectively).
Risk compensation involving initiation of new risk
relationships
On the open-ended questions, four respondents listed specific
people with whom they would begin having unprotected sex
(n = 3) and/or sharing equipment (n = 1). Three respondents gave
first names and last initials of a total of four individuals who were
confirmed to be in the study, and one person named someone not
in the study.
Structural changes to the risk network due to risk
compensation
Descriptive comparisons of the pre-vaccination and post-
vaccination networks are shown in Table 2. The expansive post-
vaccination network contained fifteen more relationships and
fifteen fewer isolates than the pre-vaccination network. In both the
expansive and sociometric networks, diameter of the post-
vaccination network was twice that of the pre-vaccination network.
The size of the main component increased from 14 to 16 due to
risk compensation; however, the overall average component size
remained similar (2.63 and 2.70, respectively). The average degree
centrality and the centralization of the post- and pre-vaccination
network were also similar.
Risk compensation resulted in a decrease in transitivity (10% to
7% in the sociometric network). The decrease in transitivity was
likely due to the fact that individuals drawn into the network
through risk compensation were not connected to other members
of the network, creating more triads that did not exhibit closure.
The number of 2-cores remained constant across the pre- and
post-vaccination networks, but a 6% increase in density, from
0.00035 to 0.00037 based on binary data, was observed (p,
0.001). As shown in Table 2, similar patterns were present when
the analyses were restricted to the sociometric network.
Discussion
Risk compensation in this sample was relatively uncommon;
only 4% reported an intention to decrease condom use with a
partner and 1% to increase sharing injection equipment if they,
their partner, or they and their partner received an HIV vaccine.
Risk compensation in the form of initiating sexual and/or
equipment sharing with new partners was similarly rare (1%).
The percentage of participants reporting an intention to risk
compensate if given a highly efficacious vaccine is nearly half that
reported in a study conducted among high-risk individuals
recruited from clinics, syringe exchange programs, and Latino
community-based organizations in Los Angeles [6] and one-fourth
that reported among men who have sex with men, African
American women, and drug users in Atlanta [39] and people who
inject drugs from Philadelphia [55]. Comparisons between the
current study and those referenced above should be made with
caution given the vastly different contexts, specifications of efficacy
(e.g., 50% and 99% [6], no specification [39,55]), and risk
compensation assessment (i.e. global measures of anticipated
behavior change vs. risk compensation intent considered on a
partner-by-partner basis). Most importantly, the contrast between
the present study’s findings and those from other settings should be
considered in light of differences in community HIV prevalence,
which is low in the present study’s target community [56]. Thus,
risk compensation intent may have been less prevalent in the
current study due to low perceived risk for HIV acquisition (i.e.,
behavioral inhibition due to perceived HIV risk is currently low,
thus behavioral disinhibition may be less applicable).
To our knowledge, the current study is the first to explore risk
compensation under three vaccination scenarios: vaccination of
Risk Compensation’s Network-Level Impact
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self, partner, and self and partner. Interestingly, levels of risk
compensation under the partner-vaccination scenario were nearly
identical to that under personal vaccination. Previous research has
generally assumed that risk compensation would be initiated by
the vaccine recipients (i.e. by asking respondents about his/her
intent to increase risk behavior if he/she was vaccinated, but not
about their likelihood of changing behavior in response to
partners’ vaccination [6,37,39]), but this study provides evidence
that partners of recipients may also initiate increased risk behavior.
This dynamic is important to explore in future HIV vaccine
Figure 2. Sexual and injection-related risk networks of respondents and named alters. Nodes are sized by degree centrality (i.e. number
of partners).
doi:10.1371/journal.pone.0101047.g002
Figure 3. Risk relationships in the expansive and sociometric networks. Number of sexual and injection relationships in the expansive
network, with numbers in parentheses indicating the subset of relationships present in the sociometric network (i.e. confirmed ties). Relationships
indicated in the shaded portions of the figure (e.g., unprotected sex and equipment sharing) comprise the expansive and sociometric pre-vaccination
networks.
doi:10.1371/journal.pone.0101047.g003
Risk Compensation’s Network-Level Impact
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acceptability research and in the context of HIV vaccine clinical
trials.
While the individual-level data are valuable, only under
examination at the dyadic level do the complex dynamics of risk
compensation become apparent. More than 500 sexual partner-
ships and nearly 70 equipment-sharing relationships were reported
by the drug users enrolled in this study. Intent to engage in sexual
risk compensation was reported for 27 relationships, and intent to
increase equipment sharing was reported for three. Thus, the 24
individuals who intended to increase their risk behavior would
actually put 35 individuals in the network at increased risk for HIV
transmission.
It is also important to note that in 5% of sexual relationships,
condom use was anticipated to increase following HIV vaccination.
This finding is corroborated by previous research reporting
decreases in sexual risk behavior among participants enrolled in
HIV vaccine clinical trials [15–17]. The potential for decreased
risk behavior is important given evidence from simulation studies
suggesting that to achieve maximal impact with a partially effective
vaccine, vaccine uptake must be coupled with behavioral risk
reduction [40,41]. From the dyadic level, it is important to note
that most of the relationships for which there was intended risk
reduction currently involved no condom use. Thus, unless the
couple decided to begin abstaining from unprotected sex
completely, the impact of behavioral risk reduction would result
in minimal change in HIV risk for first- and second-order
partners.
Individual- and dyad-level changes in risk behavior can only be
fully understood in the context of the larger social network in
which high-risk individuals are embedded. The present study
provides preliminary evidence that risk compensation could affect
the connectivity of risk networks. For example, the density of the
risk network constructed on the basis of participants’ risk
compensation intentions (i.e., accounting for new ties due to
anticipated increases in risk behavior and lost ties due to intended
decreases in risk behavior) was significantly greater than that of the
current risk network. The structural changes observed were only
slight, but conceptually important. Future studies involving
network modeling will be needed to estimate the impact of these
changes on epidemic potential. The findings of the present study
will be valuable to the parameterization of these network models.
Generalization of the study’s findings should be made with
caution and in light of its limitations. The measure of risk
compensation was based on intention; intended behavior change
may or may not correspond with patterns of future risk behavior
[57,58]. Additionally, the self-reported behavioral data were
subject to social desirability and recall bias. Also, because
participants were aware that the survey would request additional
information about each named alter, participants may have been
reluctant to provide names on the two open-ended questions
Figure 4. Risk compensation within a risk network of rural drug users. Nodes are sized by degree centrality (i.e. number of partners). The
figure does not include the 95 participants who did not someone with whom they shared equipment or had unprotected sex.
doi:10.1371/journal.pone.0101047.g004
Risk Compensation’s Network-Level Impact
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seeking information about new partners with whom they would
initiate a risk relationship in response to receiving a vaccine; thus,
the number of new partnerships may have been underestimated.
Due to time-constraints and extended length of the questionnaire
posed by the number of alter-specific questions, specific types of
sexual activity (e.g. vaginal, anal, oral) and measures of risk
compensation in the context of hypothetical pre-exposure
prophylaxis use and varying levels of vaccine efficacy were unable
to be assessed. The specification of efficacy-level in the question-
naire was important in standardizing responses, as a vaguely
worded item would create undue variance in responses with
conceptualizations of efficacy varying among respondents. The
90% efficacy level was chosen as it allowed for the most
conservative estimate of risk compensation (i.e., a level that would
greatly mitigate perceived acquisition risks and potentially lead to
near maximum compensation behaviors).
This study took place among a unique population of rural drug
users who live in a region with low HIV incidence [56]. In fact,
none of the named alters were perceived to be HIV positive. This
could have influenced estimates of risk compensation intent, as
vaccination would be expected to precipitate less behavior change
in relationships posing less risk. While these factors may dampen
the generalizability of the findings to settings with higher HIV
burden, the conceptual and methodological approach certainly
remains applicable to research in other settings. Finally, though
they would have provided valuable insight, contextual data on the
circumstances and motivations surrounding risk compensation
were not collected. In the future, qualitative approaches are
needed to fully explore the complexity of anticipated behavior
change in response to HIV vaccination.
This study provides a methodological framework in which to
examine anticipated risk compensation in future HIV vaccine
preparedness cohorts and to examine the network-level impact of
behavioral change in future HIV vaccine clinical trials. In future
research, risk compensation measures should assess not only if
people risk compensate, but also with whom they risk compensate.
This study also suggests that network-level change be considered in
the parameterization of mathematical models projecting the
Table 2. Comparison of pre- and post-vaccination risk networks.
Expansive Network Sociometric Network
Characteristic Pre-vaccination Post-vaccination Pre-vaccination Post-vaccination
Overall Number of relationships 399 414 93 100
Number of isolates 867 852 276 269
Components Number of componentsa 243 243 74 74
Size of main component 14 16 5 10
Size of components
N = 14 1 1 0 0
N = 10 1 1 0 1
N = 9 2 2 0 0
N = 8 2 2 0 0
N = 7 2 3 0 0
N = 6 3 3 0 0
N = 5 11 9 1 1
N = 4 7 8 4 4
N = 3 39 39 6 5
N = 2 175 174 63 63
Average component sizea 2.63 2.70 2.23 2.32
Centrality and centralization Degree centrality (valued) – mean
(SD)
1.53 (2.43) 1.56 (2.46) 1.77 (3.06) 1.78 (3.06)
Degree centrality (binary) – mean
(SD)
0.53 (0.80) 0.55 (0.82) 0.42 (0.59) 0.45 (0.63)
Centralization (valued) 0.43 0.43 0.20 0.20
Centralization (binary) 0.24 0.24 0.59 0.58
Cohesion Transitivity 0.69% 0.63% 10.0% 7.1%
Number of 2-cores 2 2 2 2
Density (valued) 0.9904b 0.9970b 0.0067c 0.0069c
Density (binary) 0.00035d 0.00037d 0.0019e 0.0020e
Diameter 4 8 3 6
SD: standard deviation.
aExcluding isolates.
bDifference was no statistically significant (p = 0.356).
cDifference was not statistically significant (p = 0.139).
dDifference was statistically significant (p,0.001).
eDifference was statistically significant (p = 0.019).
doi:10.1371/journal.pone.0101047.t002
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impact of risk compensation on the success of future HIV vaccines.
Finally, the findings from this study on the infrequency of intended
risk compensation, particularly that related to syringe sharing, are
encouraging and underscore the positive potential impact of a
future HIV vaccine.
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